Wednesday, July 26, 2017

Enter Title

PHSANZ Newsletter #1

Issue #1 April 2012

PHSANZ Scientific Meeting

Leave a space in your diary for the 2nd annual PSANZ scientific meeting to be held on the 15th & 16th of November 2012 - venue and full details to be announced shortly.

The complexities of pulmonary hypertension, addressing sustainable models of care for a growing population and showcasing the latest research on pulmonary hypertension across Australia and New Zealand, were high on the agenda at the Pulmonary Hypertension Society of Australia and New Zealand’s inaugural Scientific Meeting held in Sydney, in November 2011.
Jo Stratmoen was there to discuss these key issues with several presenters and produced a comprehensive report from the meeting.


Reports and Abstracts

Click to download the full report.

Click here to download a copy of the full report of the inaugural scientific meeting of the PHSANZ "Developing sustainable models of care of pulmonary hypertension" in PDF format as first published in Cardiology News, Australian Edition, Vol. 8, No. 10, 2011

Click to review the 2011 PSANZ abstracts as published in Pulmonary Circulation.

In an exciting development, all abstracts from the 2011 meeting have been accepted for publication in the journal of Pulmonary Circulation - click here to view the full list of abstracts on the Pulmonary Circulation webpage - articles 3.1 onwards.


IV Treatment Update

IV Revatio now available:

Launch of new delivery method takes to heart critical needs of patients with pulmonary arterial hypertension.

Specialists will be able to prescribe Revatio® (sildenafil citrate) in an intravenous (IV) formulation for patients with pulmonary arterial hypertension (PAH) following approval by the Therapeutic Goods Administration and inclusion on the Australian Register of Therapeutic Goods (ARTG).

Revatio is a phosphodiesterase type 5 (PDE5) inhibitor approved for the treatment of WHO functional class II and III primary PAH and PAH associated with connective tissue disease, to improve exercise capacity.

For details of the PBS listing, please refer to the PBS website:

Click here to download the full company release letter


PBS Listing of Flolan® (Epoprostenol sodium) Kits 500mcg and 1500mcg.

GlaxoSmithKline (GSK) Australia wishes to inform you that Flolan Kits will be listed on the Pharmaceutical Benefits Scheme (PBS) Schedule and will be available, as of January 1st, 2012.

Flolan is indicated for the long-term treatment, via continuous intravenous infusion, in
New York Heart Association functional class III or class IV patients with:
Idiopathic pulmonary arterial hypertension
Familial pulmonary arterial hypertension
Pulmonary arterial hypertension associated with the scleroderma spectrum of

For details of the PBS listing, please refer to the PBS website:

Click here to download the full flolan kit letter


PHSANZ Practice tools for Flolan users

The PHSANZ has developed several tools which may be helpful for Flolan users - please click on the links below to download copies of these tools.

All downloads are in PDF format - Please contact Geoff Strange for copies in other formats.


Contact Us

For more information about the goals and activities of the
Pulmonary Hypertension Society of ANZ please contact:

Geoff Strange
CEO, Pulmonary Hypertension Society ANZ Inc.
PO Box 133, Sans Souci, NSW 2219
Ph 0422 30 8585

Copyright 2011 by PHSANZ